Studies on PARP inhibitors in SCLC have been conducted in combination with other therapeutic strategies, including the treatment of recurrent SCLC and first-line treatment, as well as maintenance treatment after induction. This evidence concerns the gene PARP1 and small cell lung carcinoma.